Currently how many clinical trial sites does the company have across India ? Key clients and focus areas ?
Veeda partners with major hospitals and investigators across India to conduct clinical trials in several therapeutic areas , including oncology , psychiatry , ophthalmology and dermatology . For healthy volunteer studies , Veeda has facilities across Ahmedabad and Mehsana where it conducts clinical , bioanalytical and screening operations .
Since the company ’ s inception in 2004 , Veeda Clinical Research Limited has enabled high impact and translational research by supporting and facilitating drug discovery programs of world ’ s leading pharmaceutical and biopharmaceutical MNCs .
What role did Veeda play in successful Covid-19 vaccine development during the pandemic ? Any experiences that you would like to share ?
There has been a rising demand for drugs , vaccines , medical devices and test kits for COVID- 19 infection and its complications , which created a huge demand for CRO services amidst pandemic situations . Global and Indian CROs have now been working on trials wherein drugs , vaccines and medical devices are being tested in COVID-19 patients . The pandemic has significantly fast tracked the regulatory approval timelines paving way for a
Veeda Clinical Research Limited offers a diverse and comprehensive portfolio of clinical research services . The company has state-of-the-art clinical research facilities , resources and scientific expertise for investigator led and commercially sponsored large scale multifunctional clinical trials .
higher growth of the CRO industry .
CROs are now positioning themselves as end-to-end solution providers making their services more cost effective , time saving and offering services across the value chain . Thus , participants are resorting to M & A activities to gain access to specific service portfolios , such as preclinical development and bio-analytical testing .
Veeda Clinical Research completed the Phase 1 bridging study and is currently conducting the Phase II / III double-blinded placebocontrolled study for a novel fusion protein based vaccine , developed by one of our USbased clients , which has demonstrated very encouraging results . Besides this , Veeda successfully completed a Phase II study for a phytochemical product for the treatment of mild to moderate COVID with beneficial effect on long COVID symptoms .
How has the acquisition of pre-clinical CRO , Bioneeds helped Veeda to expand its business capabilities & revenue generation ?
With acquisition of Bioneeds , we have gained comprehensive pre-clinical research capabilities , across two facilities in Bangalore to support preclinical drug development solutions . With Bioneeds , we are now able to offer a wide range of pre-clinical services complimented by our early phase clinical services to innovator pharmaceutical companies in order to provide them with comprehensive drug development support .
Our capabilities are distinct with multiple adjacencies and we see significant synergies across our clients and geographical markets to cross leverage our capabilities and offer customized integrated research solutions for our clients . We are working towards further aligning our capabilities , systems , processes and people to realize the full potential of our combination .
Please tell us more about Ingenuity , your joint venture with Somru Bioscience , Canada and how it is adding value within the biopharma space ?
Ingenuity Biosciences expands its capabilities in biosimilars and offers complete bioassay
BIOVOICENEWS . COM 09